To determine whether LILRB2 mediates the tumor-support effects of cystatin C, hCD34+ humanized mice bearing SK-MEL-5-hcystatin C tumors were treated with an anti-LILRB2 blocking antibody when the tumors reached 100–120 mm3. Here, CST3 is linked to neoplasm.